|
GEMFIBROZIL INCREASED PLASMA CONCENTRATION OF THE DRUG SIGNIFICANTLY
|
INHIBITS CLEARANCE OF THE DRUG CAUSING EXTREEM HIGH LEVELS OF TRIGLYCERIDES & PANCREATITIS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
LIPID LOWERING DRUGS LIKE CLOFIBRATE & OTHERS INCREASE HEPATIC CHOLESTROL SECRETION & ENCOURAGE CHOLESTROL GALL STONE FORMATION AND HENCE MAY COUNTERACT THE EFFECTIVENESS OF URSODIOL
|